| 000 | 01611 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250518023929.0 | ||
| 264 | 0 | _c20190909 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a0028-2685 | ||
| 024 | 7 |
_a10.4149/neo_2018_180824N644 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMaisnar, V | |
| 245 | 0 | 0 |
_aLenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies. _h[electronic resource] |
| 260 |
_bNeoplasma _cMay 2019 |
||
| 300 |
_a499-505 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadverse effects |
| 650 | 0 | 4 | _aAntineoplastic Combined Chemotherapy Protocols |
| 650 | 0 | 4 | _aCzech Republic |
| 650 | 0 | 4 |
_aDexamethasone _xadverse effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLenalidomide _xadverse effects |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdrug therapy |
| 650 | 0 | 4 |
_aRegistries _xstatistics & numerical data |
| 650 | 0 | 4 | _aSlovakia |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aStefanikova, Z | |
| 700 | 1 | _aSpicka, I | |
| 700 | 1 | _aPour, L | |
| 700 | 1 | _aMinarik, J | |
| 700 | 1 | _aFlochova, E | |
| 700 | 1 | _aRadocha, J | |
| 700 | 1 | _aGregora, E | |
| 700 | 1 | _aStecova, N | |
| 700 | 1 | _aJelinek, T | |
| 700 | 1 | _aJungova, A | |
| 700 | 1 | _aKralikova, E | |
| 700 | 1 | _aBrozova, L | |
| 700 | 1 | _aHajek, R | |
| 773 | 0 |
_tNeoplasma _gvol. 66 _gno. 3 _gp. 499-505 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.4149/neo_2018_180824N644 _zAvailable from publisher's website |
| 999 |
_c29392388 _d29392388 |
||